Kyowa Hakko Kirin To Resume Development Of Kidney Disease Drug Bardoxolone Methyl In Japan

Kyowa Hakko Kirin will restart its Phase II trials with bardoxolone methyl for the treatment of chronic kidney disease in type 2 diabetes patients, the company announced on July 2.